49 results
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
27 Mar 24
Evaxion Announces Business Update and Full Year 2023 Financial Results
8:30am
Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous … focusing on value realization via Targets, Pipeline and Responders based upon a muti-partner approach, we are enthusiastic about the prospects
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
19 Mar 24
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
8:17am
models, PIONEER™, ObsERV™, EDEN™ and RAVEN™, we can identify clinically relevant vaccine targets within hours.
Christian Kanstrup, CEO of Evaxion … effective personal cancer vaccines
The EDEN™ model outperforms reverse vaccinology finding novel targets in hours instead of years. The EDEN™ designed EVX-B2
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
20 Feb 24
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
7:32am
proprietary platform, AI-Immunology™, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues
F-1/A
EVAX
Evaxion Biotech A/S
30 Jan 24
Registration statement (foreign) (amended)
3:16pm
vaccine targets. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options through AI-Immunology™ … our three-pronged business model focusing on Targets, Pipeline and Responders. This value realization is to be pursued via a multi-partner approach
6-K
EX-99.1
fssr5x0a
24 Jan 24
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
2:11pm
F-1
cc5 hbh2lcu
12 Jan 24
Registration statement (foreign)
5:17pm
6-K
EX-99.1
b1t6houokoeo q9bvg
19 Dec 23
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
4:45pm
6-K
EX-99.1
tds5mpy1zl8
28 Nov 23
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
8:27am
6-K
EX-99.1
1g2r7f 4cenbr
31 Oct 23
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
11:22am
6-K
EX-99.2
ehmth8grcwuml7eyn
27 Sep 23
Current report (foreign)
4:45pm
6-K
EX-99.1
iewzexenk9oxqokpv
27 Sep 23
Current report (foreign)
4:45pm
424B4
hyj4 4xig0yg
13 Sep 23
Prospectus supplement with pricing info
4:45pm
6-K
EX-99.1
e3yym qisj3d0us6px
11 Sep 23
Current report (foreign)
8:17am
POS AM
jyuuops43
25 Aug 23
Prospectus update (post-effective amendment)
5:00pm
6-K/A
EX-99.1
ls1hlpw
18 Aug 23
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
9:28am
6-K
EX-99.2
gas huk4p5d7049a
17 Aug 23
Current report (foreign)
4:58pm
6-K
EX-99.1
yed27skjnpgg8tuv
17 Aug 23
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
4:45pm
6-K
EX-99.1
fiuhttxpx 5a
1 Aug 23
Evaxion announces financing commitments totaling up to USD 20 million with Negma Group
7:00am
6-K
EX-99.1
bid sdicu
5 Jun 23
Current report (foreign)
7:44am